A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

• Status: Completed
• Trial end date: 2021-04-27
• Target enrollment: 0
• Participant gender: Male

Summary

This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men.

Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by chance. Non-Asian participants will get NNC0194-0499.

Participants will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on the stomach.

The study will last for a maximum of 66 days. Participants will have 8 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights).

The study includes blood sampling. Participants will not be able to take part in the study if the study doctor thinks there is a risk for participants health.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Male, aged 20-55 years (both inclusive) at the time of signing informed consent

• For Japanese subjects only, both parents of Japanese descent. For non-Asian subjects only, both parents of non-Asian descent

• Body mass index (BMI) between 23.0 and 34.9 kg/m^2 (both inclusive)

• Body weight greater than or equal to 60 kg

Exclusion Criteria:

• Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol

• Subjects aged above or equal to 40 years with an estimated 10-year atherosclerotic cardiovascular disease risk (as described in the American College of Cardiology and the American Heart Association Prevention Guideline) greater than or equal to 5 percentage